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PTEN is a tumor suppressor gene mutated in many human cancers, and its expression is reduced or absent in 
almost half of hepatoma patients. We used the Cre-loxP system to generate a hepatocyte-specific null mutation 
of Pten in mice (AlbCrePtenflox/flox mice). AlbCrePtenflox/flox mice showed massive hepatomegaly and steatohepatitis 
with triglyceride accumulation, a phenotype similar to human nonalcoholic steatohepatitis. Adipocyte-spe-
cific genes were induced in mutant hepatocytes, implying adipogenic-like transformation of these cells. Genes 
involved in lipogenesis and β-oxidation were also induced, possibly as a result of elevated levels of the transac-
tivating factors PPARγ and SREBP1c. Importantly, the loss of Pten function in the liver led to tumorigenesis, 
with 47% of AlbCrePtenflox/flox livers developing liver cell adenomas by 44 weeks of age. By 74–78 weeks of age, 
100% of AlbCrePtenflox/flox livers showed adenomas and 66% had hepatocellular carcinomas. AlbCrePtenflox/flox mice 
also showed insulin hypersensitivity. In vitro, AlbCrePtenflox/flox hepatocytes were hyperproliferative and showed 
increased hyperoxidation with abnormal activation of protein kinase B and MAPK. Pten is thus an important 
regulator of lipogenesis, glucose metabolism, hepatocyte homeostasis, and tumorigenesis in the liver.
Introduction
PTEN is a ubiquitously expressed tumor suppressor gene (1) that is 
mutated in many human sporadic cancers as well as in tumorigenic 
hereditary disorders such as Cowden disease. PTEN is a multifunc-
tional phosphatase whose lipid phosphatase activity is associated 
with tumor suppression (2). The major substrate of PTEN is phos-
phatidylinositol-3,4,5-triphosphate (PIP3) (3), a lipid second-mes-
senger molecule generated by the action of PI3Ks. PI3Ks are activated 
by a range of stimuli, including various cytokines and insulin. PIP3 
activates the serine-threonine kinase protein kinase B (PKB/Akt), 
which is involved in antiapoptosis, proliferation, and oncogenesis.
While mutation of PTEN is an infrequent event in hepatocytes 
(4), PTEN protein expression is decreased or absent in about half of 
primary hepatoma patients (5). Decreased PTEN expression corre-
lates with increased tumor grade, advanced disease stage, and poor 
prognosis (5). In vitro, administration of hepatocyte growth factor 
induces cellular proliferation via activation of the PI3K pathway 
(6), and hepatocyte cell lines that activate PKB/Akt resist apoptosis 
(7). These findings suggest that PTEN is important for maintain-
ing homeostasis and preventing oncogenesis in the liver.
The PPARs belong to the nuclear receptor superfamily (8). The 
PPAR subfamily comprises three isotypes: PPARα, PPARγ, and 
PPARβ/δ. These proteins all possess a highly conserved DNA-binding 
domain that recognizes peroxisome proliferator response elements 
in the promoter regions of target genes involved in lipid homeostasis 
(9). In particular, PPARγ is a key regulator of adipogenesis (9). Forced 
expression of PPARγ initiates the differentiation of fibroblasts into 
adipocytes via the induction of adipocyte-specific genes, leading 
to lipid accumulation (8). Similarly, forced expression of PPARγ 
in the liver triggers adipocyte-specific gene expression and steato-
sis (hepatic lipid accumulation) (10). The related receptor PPARα 
regulates enzymes involved in the β-oxidation of fatty acids, and is 
essential for the pleiotropic responses induced in the liver by per-
oxisome proliferators (11). Forced expression of PPARγ upregulates 
enzymes involved in PPARα-regulated peroxisomal fatty acid β-oxi-
dation, including acyl-CoA oxidase (AOX), peroxisomal enoyl-CoA 
hydratase/3-hydroxyacyl-CoA dehydrogenase bifunctional protein 
(L-PBE), and peroxisomal 3-ketoacyl-CoA thiolase (PTL) (10, 12).
We have previously generated null Pten–/– mice as well as mice 
bearing tissue-specific Pten mutations in T, B, neuronal, cardiac 
muscle, and germ cells, as well as keratinocytes (all reviewed in 
ref. 13). In this study, we demonstrate that hepatocyte-specific 
Pten deficiency leads to steatohepatitis associated with increased 
PPARγ expression, insulin hypersensitivity, and liver tumorigen-
esis. PTEN is thus important for the maintenance of normal 
hepatocyte glucose metabolism as well as the prevention of adip-
ogenic or tumorigenic transformation.
Methods
Generation of AlbCrePtenflox/flox mice. Ptenflox/flox mice (129Ola × 
C57BL6/J F2), generated as previously described (14), were mated 
to AlbCre transgenic mice (C57BL6/J background; The Jackson 
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Laboratory, Bar Harbor, Maine, USA) (15), in which expression of 
Cre is controlled by the promoter of the hepatocyte-specific gene 
Albumin. Offspring carrying AlbCre and two copies of the floxed 
Pten allele (AlbCrePtenflox/flox), AlbCre plus one copy of the floxed 
Pten allele (AlbCrePtenflox/+), and AlbCre plus two copies of the WT 
Pten allele (AlbCrePten+/+) were used in the analyses as homozygous 
mutant (AlbCrePtenflox/flox), heterozygous mutant (AlbCrePtenflox/+), 
and WT (AlbCrePten+/+) mice, respectively.
Mice of 40 weeks of age that were part of the tumor burden 
experiments were excluded from all histological and biochemical 
assays except those described in Results under the heading Tumor 
formation in the livers of AlbCrePtenflox/flox mice. All animal experiments 
were approved by the Institutional Review Board of the Akita Uni-
versity School of Medicine.
PCR analysis of Pten genotypes. Genomic DNA from mouse tails 
was isolated and amplified by PCR as described (16). Sequenc-
es of sense and antisense primers for the floxed and WT Pten 
alleles and the AlbCre transgene are given in Supplemental Table 
1 (supplemental material available at http://www.jci.org/cgi/
content/full/113/12/1774/DC1). Amplified fragments of 512 
bp (floxed Pten), 413 bp (WT Pten), and about 550 bp (AlbCre 
transgene) were obtained.
Determination of total liver cell numbers. Livers were perfused in situ 
with oxygenated 0.5 mM EGTA containing calcium-free salt solu-
tion (10 ml/min at 37°C for 5 minutes), followed by perfusion 
with 0.04% collagenase type I (Wako Pure Chemicals Industries, 
Osaka, Japan) for 10 minutes as previously described (17). Livers 
were minced in a petri dish, filtered using Cell Strainer (Becton 
Dickinson Labware, Bedford, Massachusetts, USA), and repeatedly 
washed with PBS. Residual liver cells were collected in the same 
tube by pressing through the Cell Strainer using a syringe, and the 
total cell number was determined by Giemsa nuclear staining.
Southern and Western blots. Genomic Southern blots of total liver 
cell DNA were performed as described (16). For PKB/Akt, forkhead 
box transcription factor class O-1 (Foxo1, also known as FKHR), 
and MAPK assays, 100 μg of total liver cell lysate were analyzed 
by Western blotting as described (18). Antibody specific to the N 
terminus of Pten and to actin were from Santa Cruz Biotechnol-
ogy (Santa Cruz, California, USA), while antibodies specific to 
phospho-PKB/Akt (Ser473), to total PKB/Akt, to phospho-MAPK 
(p42/p44; Thr202/Tyr204), to total MAPK (p42/p44), to phospho-
Foxo1 (FKHR; Ser256), and to total Foxo1 were from New England 
Biolabs Inc. (Beverly, Massachusetts, USA).
Histology and immunohistology. Formalin-fixed tissues were embed-
ded in paraffin using standard procedures. Sections (4 μm thick) 
were cut and stained with either H&E for standard microscopy 
or Azan stain to show fibrosis. To visualize lipids, frozen sec-
tions (5 μm thick) were stained with Oil Red O (Nakarai Tesque 
Inc., Kyoto, Japan) and counterstained with hematoxylin. For 
immunohistochemistry, sections from frozen tissues were fixed 
in 4% paraformaldehyde in PBS, blocked with 5% normal donkey 
serum (Chemicon International, Temecula, California, USA) plus 
3% BSA, and incubated overnight with rabbit anti-mouse adipo-
nectin antibody (provided by P.E. Scherer, Albert Einstein College 
of Medicine, New York, New York, USA) followed by Cy3-conju-
gated AffiniPure donkey anti-rabbit IgG (H+L) (The Jackson Labo-
ratory) as a secondary antibody. To reveal adiponectin/albumin 
co-staining, the same sections were also incubated with rabbit 
anti-mouse albumin antibody (Biogenesis Ltd., Poole, United King-
dom) labeled with Alexa Fluor 488 using a rabbit IgG labeling kit 
(Molecular Probes Inc., Eugene, Oregon, USA). Double-stained sec-
tions were analyzed using confocal fluorescent microscopy (Leica 
Microsystems Inc., Deerfield, Illinois, USA). Peroxisomes in livers 
were detected by staining for catalase. Frozen liver sections (9 μm 
thick) were incubated overnight at 37°C with 5 mM 3,3ʹ-diamino-
benzidine (DAB) substrate in 0.1 M glycine-NaOH (pH 10.5)–0.15% 
H2O2. Nuclear counterstaining was performed with hematoxylin.
Electron microscopy. Mouse livers were perfused with 1.6% glu-
taraldehyde (TAAB Laboratory Equipment Ltd., Reading, United 
Kingdom), excised, and fixed at 4°C for 1 hour prior to examina-
tion using standard electron-microscopic techniques.
Lipid analysis. Mice were starved for a minimum of 8 hours and 
sacrificed by CO2 asphyxiation. Blood was collected aseptically by 
cardiac puncture and centrifuged (13,000 g, 5 minutes, 4°C) to col-
lect plasma. Total lipids were extracted from the liver as previously 
described (19). Levels of free cholesterol, cholesterol esters, FFAs, 
phospholipids and triglycerides in the liver, and total cholesterol, 
triglycerides, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), and alkaline phosphatase (ALP) in serum were 
determined by colorimetric, UV kinetic, or enzymatic assays fol-
lowing the various manufacturers’ protocols (Sigma-Aldrich, St. 
Louis, Missouri, USA, and Wako Pure Chemicals Industries). 
The fatty acid composition of the hepatic lipid fraction was 
analyzed by gas chromatography (20). After methanolysis by a 
modified Morrison and Smith method in which boron trifluoride 
served as the catalyst (20, 21), fatty acid methyl esters were ana-
lyzed using a Shimadzu GC-7A gas chromatograph (Shimadzu 
Corp., Kyoto, Japan) equipped with a capillary column of 30 m 
length × 0.3 mm diameter, coated with ethylene glycol succinate. 
The concentration of each fatty acid and the total amount of each 
fatty acid per liver were calculated as described previously (22).
RT-PCR. Total RNA was extracted using TRIzol (Life Technolo-
gies Inc., Gaithersburg, Maryland, USA) according to the manufac-
turer’s instructions. Total RNA (1 μg) was reverse-transcribed using 
MMTV reverse transcriptase and the PCR protocol recommended 
by the manufacturer (Life Technologies Inc.). Primers for PCR reac-
tions and numbers of PCR cycles are given in Supplemental Table 
1. Amplified product sizes were as follows: PPARγ, 506 bp; PPARα, 
463 bp; SREBP1c, 116 bp; C/EBPα, 411 bp; C/EBPβ, 195 bp; C/
EBPδ, 280 bp; adiponectin, 132 bp; adipsin, 265 bp; aP2, 83 bp; 
fatty acid synthetase (FAS), 327 bp; acetyl-CoA carboxylase (ACC), 
729 bp; stearoyl-CoA desaturase (SCD1), 271 bp; AOX, 536 bp; 
L-PBE, 356 bp; PTL, 293 bp; β-actin, 663 bp. The intensity of each 
band was measured using NIH image software.
BrdU staining. Mice were fed BrdU (3 mg/ml, Sigma-Aldrich) dis-
solved in drinking water for 4 days and sacrificed. Tissues were fixed 
in 10% neutral-buffered formalin and embedded in paraffin. Sec-
tions (4 μm thick) were deparaffinized and treated with HCl (2 N) 
for 20 minutes followed by 0.1% trypsin type II (crude from porcine 
pancreas; Sigma-Aldrich) for 20 minutes. Treated sections were incu-
bated with normal goat serum (DAKO A/S, Glostrup, Denmark) for 
1 hour, then with mouse anti-BrdU antibody (Becton Dickinson 
and Co., Franklin Lakes, New Jersey, USA) for 1 hour. Peroxidase-
conjugated goat anti-mouse IgG (DAKO A/S) and DAB were used 
to detect BrdU incorporation. Normal mouse serum was used as the 
negative control. Slides were counterstained with hematoxylin.
TUNEL assay. Apoptosis was determined by the TUNEL assay 
using the In Situ Cell Death Detection Kit, AP (Boehringer 
Mannheim GmbH, Mannheim, Germany). The slides were 
counterstained with methyl green.
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H2O2 Production. Liver samples were homogenized (1% w/v) in 
lysis buffer (0.2 M Tris-HCl, pH 8.0, 0.1 M EDTA, 2% SDS contain-
ing 20 mM NaN3 to inhibit endogenous catalase), and H2O2 was 
assayed using phenol red.
Insulin and glucose tolerance tests and serum insulin measurement. 
Insulin and glucose tolerance tests were performed on animals 
that had been starved overnight. Glucose (2 g/kg body weight) 
or human regular insulin (Eli Lilly and Company, Indianapolis, 
Indiana, USA) (0.75 U/kg body weight) was administered orally 
or intraperitoneally, respectively. Blood glucose values at 0, 30, 
60, 90, and 120 minutes were measured in tail venous blood 
using an automated glucose monitor (ARKRAY Inc., Kyoto, 
Japan). Serum insulin levels following overnight starvation were 
measured using an ELISA kit according to the manufacturer’s 
protocol (Mercodia, Uppsala, Sweden). 
Results
Generation of AlbCrePtenflox/flox mice. Hepatocyte-specific Pten-deficient 
mice were generated as described in Figure 1A. AlbCrePtenflox/flox mice 
were born alive and appeared healthy. Southern blotting of DNA from 
Figure 1
Generation of hepatocyte-specific Pten-deficient (AlbCrePtenflox/flox) mice. (A) Targeting strategy. Exons of the murine Pten gene are rep-
resented by filled boxes, loxP sites by filled arrowheads. The probe used to analyze Southern blots is indicated and has been described 
previously (14). The floxed (Ptenflox) and deleted (PtenΔ) alleles are shown. (B) Genomic Southern blot. DNA (20 μg) extracted from total liver 
cells of the indicated genotypes was digested with HindIII. The vast majority of total liver cells from AlbCrePtenflox/flox mice showed deletion of 
the Pten gene. (C) Western blot analysis of Pten protein expression by total liver cells of the indicated genotype. Actin, loading control. Liver 
samples were obtained from 8-week-old mice.
Figure 2
Liver anomalies in AlbCrePtenflox/flox mice. 
(A and B) Macroscopic analyses of liv-
ers. Hepatomegaly and pale coloring 
was observed in 10-week-old (A) and 40-
week-old (B) AlbCrePtenflox/flox mice. For 
all panels: +/+, AlbCrePten+/+; flox/+, Alb-
CrePtenflox/+, and flox/flox, AlbCrePtenflox/flox 
mice. (C) Decreased liver weight. The liver 
weight/body weight ratio was analyzed in 
+/+, flox/+, and flox/flox mice at 10 weeks 
(n = 11 mice/group) and 40 weeks (n = 15). 
For all panels, where appropriate, results 
are expressed as the mean ± SEM of the 
indicated number of mice per group. Statis-
tical differences were determined using the 
Student’s t test: *P < 0.05. (D) Decreased 
number of liver cells. Absolute numbers 
of total liver cells were determined in +/+, 
flox/+, and flox/flox livers at 10 weeks (n = 7 
mice/group) and 40 weeks (n = 7).
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total liver cells of 8-week-old mice showed that Cre-mediated recom-
bination of loxP sites deleted much of the 6.0-kb Ptenflox allele in the 
majority of cells, leaving the 2.3-kb PtenΔ allele (Figure 1B). Western 
blotting confirmed a dramatic reduction of Pten protein in livers of 8-
week-old mutant mice (Figure 1C). Since hepatocytes compose about 
80% of the total liver cell population (23), the Pten gene was rendered 
null in the vast majority of liver cells in AlbCrePtenflox/flox mice. The 
faint Pten band visible in the AlbCrePtenflox/flox liver in Figure 1C is 
probably due to nonparenchymal liver cells such as bile duct cells, 
Kupffer cells, lymphocytes, and endothelial cells (23), which do not 
activate the albumin promoter. Our results are consistent with previ-
ous assessments of the efficiency of Cre-loxP recombination in total 
liver cells of AlbCreTg mice, observed to be 40% in newborn mice and 
75% in 3-week-old mice (15).
Liver anomalies in AlbCrePtenflox/flox mice. The livers of 10-week-
old AlbCrePtenflox/flox mice were enlarged and light-colored (Figure 
2A). At 40 weeks, the livers of AlbCrePtenflox/flox mice were further 
enlarged and homogeneously white in color (Figure 2B). The liver 
weight per body weight ratio of AlbCrePtenflox/flox mice was increased 
twofold over that of the WT at 10 weeks, and threefold at 40 
weeks (Figure 2C). A more modest but still statistically significant 
increase in total liver weight was also observed in AlbCrePtenflox/+ 
mice at 40 weeks. While absolute numbers of AlbCrePtenflox/flox total 
liver cells were almost normal at 10 weeks, they had increased sig-
nificantly (by 1.5-fold) at 40 weeks (Figure 2D).
Steatohepatitis in AlbCrePtenflox/flox mice. We undertook a closer 
histological examination of cells in the livers of 10-week-old 
AlbCrePtenflox/flox mice. The nuclei of these cells were still cen-
trally located, but the cytoplasm was weakly eosinophilic and 
contained numerous microvesicular vacuoles. The vacuolar change 
was observed mainly around the central vein (Figure 3A, first and 
second rows). Oil Red O staining (Figure 3A, third row) and elec-
tron-microscopic examination (Figure 3A, fifth row) revealed that 
the vacuoles contained lipids. No fibrotic changes (Figure 3A, 
fourth row), as determined by Azan staining, and no peroxisome 
proliferation (Supplemental Figure 1) as determined by DAB stain-
ing were evident at 10 weeks. Interestingly, steatotic changes were 
more prominent in male than female mice (data not shown).
Figure 3
Steatohepatitis in AlbCrePtenflox/flox mice. (A) Histological analyses of liver sections from +/+ and flox/flox mice sacrificed at 10 weeks of age. The 
first and second rows show a lower (×10) and higher (×400) magnification of H&E-stained livers, respectively. Lipid accumulation was observed 
around the central vein area (C), whereas the periportal vein area (P) was almost intact. Lipid accumulation was confirmed by Oil-red O staining 
(third row). Liver fibrosis was not evident as determined by Azan staining (fourth row). Lipid accumulation was also confirmed by electron micros-
copy (fifth row). (B) Histological analyses of liver sections of +/+, flox/+, and flox/flox mice (without precancerous tumors) sacrificed at 40 weeks of 
age. The first and second rows show a lower (×10) and higher (×400) magnification of H&E-stained liver sections, respectively. The third row (left) 
shows an accumulation of lipid in the mutant liver that resembles adipocytes in a fat tissue. Additional features of mutant livers were steatohepatitis 
and Mallory bodies (third row right, arrows), sinusoidal fibrogenic changes (fourth row left), and an accumulation of inflammatory cells (fourth row 
right). Focal lipid-laden hepatocytes within diffuse mild fatty changes were noted in the livers of some flox/+ mice (fifth row).
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By 40 weeks, AlbCrePtenflox/flox livers showed fatty changes of 
increased severity throughout the hepatic lobule (Figure 3B, 
first and second rows). The vacuoles had coalesced to form large 
unilobular vacuoles that displaced the nucleus to the periphery. 
Indeed, the histological picture of the aged mutant liver resembled 
that of adipocytes in fat tissues (Figure 3B, third row left). Mal-
lory bodies were frequently observed in the mutant hepatocytes 
(Figure 3B, third row right). Mild sinusoidal fibrogenic changes 
(Figure 3B, fourth row left) and accumulations of lobular inflam-
matory cells (such as lymphocytes and neutrophils) (Figure 3B, 
fourth row right) were also observed. These histological findings 
are strikingly similar to those reported for nonalcoholic steato-
hepatitis (NASH) in humans (24). Focal lipid-laden hepatocytes 
within diffuse fatty changes were noted in some AlbCrePtenflox/+ 
livers examined (Figure 3B, fifth row right).
Accumulation of triglyceride and hepatic damage in AlbCrePtenflox/flox mice. 
We examined AlbCrePten+/+, AlbCrePtenflox/+, and AlbCrePtenflox/flox mice 
for the status of various biochemical parameters (Table 1). AST, 
ALT, and ALP levels were not increased in the sera of 10-week-
old AlbCrePtenflox/flox mice but were significantly elevated in 
40-week-old mutants. More modest increases in AST and ALT 
levels were observed in 40-week-old AlbCrePtenflox/+ mice. Thus, 
steatohepatitis induced in the absence of Pten damages liver 
function in older mice.
We next evaluated the concentrations of various lipids in sam-
ples of liver extracts (Table 1). Triglyceride and cholesterol ester 
levels were significantly increased in the livers of 10-week-old 
AlbCrePtenflox/flox mice, and dramatically elevated in the livers of 
40-week-old mutants. However, there were no significant differ-
ences in liver concentrations of FFAs, free cholesterol, or phos-
pholipids. Gas chromatographic analysis of total fatty acid com-
position showed that 16-carbon monounsaturated fatty acids 
(C16:1) and C18:1 fatty acids were significantly increased in the 
livers of 10-week-old AlbCrePtenflox/flox mice. C16:0, C16:1, C18:0, 
C18:1, and C18:2 fatty acids were also significantly increased in 
the livers of 40-week-old AlbCrePtenflox/flox mice, with the greatest 
increments in C16:1 and C18:1 molecules. Thus, the loss of Pten 
disrupts several aspects of fat metabolism in the liver.
Expression of adipogenic and lipogenic genes in Pten-deficient 
hepatocytes. To investigate the triglyceride accumulation in 
AlbCrePtenflox/flox livers, we measured the expression of several 
adipogenic, lipogenic and lipid β-oxidation–related genes in 
hepatocytes of AlbCrePten+/+ and AlbCrePtenflox/flox mice (Figure 
4A). RT-PCR analysis revealed a dramatic induction of PPARγ, 
a key transcriptional activator for adipocyte differentiation 
(8). Downstream target genes of PPARγ, such as the adipo-
cyte-specific genes adipsin, adiponectin, and aP2, were also 
induced. Expression levels of PPARα, C/EBPα, C/EBPδ, and 
other transcriptional activators important for adipocyte differ-
entiation were normal, while expression of C/EBPβ was slightly 
reduced. Moderate increases were observed in the expression 
of the PPARα-regulated peroxisomal fatty acid β-oxidation 
system genes AOX, L-PBE, and PTL. Our data suggest that 
overexpression of PPARγ induced by an absence of Pten can 
force upregulation of these PPARα-regulated genes, consistent 
with previous reports that very high levels of PPARγ can activate 
transcription of PPARα target genes (10, 12).
Another transcription factor that regulates lipid synthesis is 
SREBP-1c (25). SREBP-1c expression was moderately elevated in 
AlbCrePtenflox/flox livers, as was that of fatty acid–modifying enzymes 
acting downstream of SREBP-1c such as FAS, ACC, and SCD1. 
These results indicate that the striking increase in PPARγ observed 
in the absence of Pten is associated with a moderate increase in 
expression of SREBP-1c and its target genes.
Table 1
Biochemical analyses of serum and liver extracts of AlbCrePten+/+, AlbCrePtenflox/+, and AlbCrePtenflox/flox mice
 10 weeks old (n = 4)   40 weeks old (n = 4)
 +/+ flox/+ flox/flox +/+ flox/+ flox/flox
Serum
AST (IU/l) 80 ± 8 78 ± 3 95 ± 15 77 ± 7 136 ± 6A 337 ± 102A
ALT (IU/l) 36 ± 5 39 ± 4 56 ± 10 36 ± 2 55 ± 6A 462 ± 167A
ALP (IU/l) 233 ± 25 242 ± 37 315 ± 45 191 ± 42 202 ± 46 620 ± 86A
Triglyceride (mg/dl) 51 ± 4 45 ± 4 46 ± 1 59 ± 4 60 ± 5 64 ± 3
Total cholesterol (mg/dl) 92 ± 4 92 ± 5 116 ± 11 138 ± 19 115 ± 24 213 ± 47
Liver
Triglyceride (mg/g) 9.8 ± 0.3 11.4 ± 1.9 87.4 ± 19.8A 27.7 ± 8.5 32.3 ± 7.7 215.2 ± 31.1A
FFA (μEq/g) 0.41 ± 0.08 0.34 ± 0.04 0.42 ± 0.04 0.41 ± 0.08 0.34 ± 0.04 0.42 ± 0.04
Free cholesterol (mg/g) 0.63 ± 0.01 0.62 ± 0.02 0.62 ± 0.05 0.63 ± 0.01 0.62 ± 0.02 0.62 ± 0.03
Cholesterol esters (mg/g) 0.20 ± 0.09 0.18 ± 0.10 0.44 ± 0.05A 0.22 ± 0.10 0.29 ± 0.13 1.46 ± 0.36A
Phospholipid (mg/g) 4.7 ± 1.0 5.4 ± 0.2 5.3 ± 0.1 5.1 ± 0.3 4.7 ± 0.1 4.1 ± 0.4
Fatty acid composition
C16:0 (mg/liver) 47 ± 12  108 ± 20 12 ± 1  131 ± 14A
C16:1 (mg/liver) 2 ± 1  10 ± 2A 1.4 ± 0.1  21 ± 4A
C18:0 (mg/liver) 17 ± 0.4  57 ± 27 3 ± 0.3  13 ± 1A
C18:1 (mg/liver) 36 ± 13  163 ± 39A 11 ± 0.4  281 ± 19A
C18:2 (mg/liver) 63 ± 19  81 ± 12 8 ± 1  23 ± 3A
Results are expressed as the mean ± SEM for four mice per group. Statistically significant differences from the WT are shown with an asterisk. Experiments 
were repeated three times. Statistical differences were determined using the Student’s t test: AP < 0.05.
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We next performed immunohistochemistry to visualize mutant 
hepatocytes expressing adiponectin (adipocyte marker) and albu-
min (hepatocyte marker). Unlike the WT, most AlbCrePtenflox/flox 
hepatocytes showed a vivid granular staining pattern with anti-
body specific to adiponectin (Cy3) (Figure 4B). These adiponectin+ 
cells also stained positively for albumin (Alexa Fluor 488), con-
firming that the mutant hepatocytes had acquired expression of 
an adipocyte-specific marker.
Glucose metabolism in AlbCrePtenflox/flox mice. The PI3K-PKB/Akt 
pathway is activated by insulin signaling. To determine if hepatic 
Pten deficiency affected glucose metabolism, six AlbCrePten+/+ and 
six AlbCrePtenflox/flox mice of 12 weeks of age were starved overnight 
and subjected to glucose and insulin tolerance tests. AlbCrePtenflox/flox 
mice had significantly lower glucose levels than the WT both 
before and after oral glucose administration (Supplemental 
Figure 2A). Intraperitoneal insulin injection reduced glu-
cose levels in the mutants by a significantly greater margin 
compared with the WT even at the 15-minute mark (Supple-
mental Figure 2B), indicating insulin hypersensitivity. Serum 
insulin was significantly reduced in AlbCrePtenflox/flox mice 
(Supplemental Figure 2C). Thus, Pten deficiency alters both 
baseline glucose metabolism and insulin sensitivity.
Tumor formation in the livers of AlbCrePtenflox/flox mice. Patho-
logical examination of 20 AlbCrePten+/+ and 20 AlbCrePtenflox/+ 
mice revealed no evidence of hepatic tumors by 40–44 
weeks of age. In contrast, macroscopic hepatic tumors were 
clearly present in 66% (6/9) of male and 30% (3/10) of female 
AlbCrePtenflox/flox mice at this age (Figure 5A). Microscopic 
examination of AlbCrePtenflox/flox livers revealed nodular lesions 
resembling liver adenomas that compressed the surrounding 
nontumorous liver parenchyma (Figure 5B). Cells with large 
droplets in the cytoplasm were prominent in most adenomas. 
No such nodular lesions were observed in AlbCrePten+/+ (data 
not shown) or AlbCrePtenflox/+ (Figure 5C) livers. Six male and 
six female AlbCrePtenflox/flox mice were monitored until sacrifice 
at age 74–78 weeks. Livers of all these animals showed macro-
scopic hepatic tumors (Figure 5D). Histological examination 
revealed that hepatocellular carcinomas (HCCs) were present 
in five of six male and three of six female AlbCrePtenflox/flox mice 
(Figure 5E), while four mutant mice showed benign liver adenomas 
(data not shown). The HCCs had developed within liver adenomas, 
and the HCC cells contained many fewer cytoplasmic lipid droplets 
than the liver adenoma cells. Two AlbCrePtenflox/flox mice with HCC 
also showed lung metastases (Figure 5F). These findings indicate 
that Pten function is essential for preventing liver tumorigenesis.
Tumorigenic anomalies in Pten-deficient hepatocytes. To investigate 
the molecular basis for the elevated number of hepatocytes and 
tumor formation in AlbCrePtenflox/flox mice, hepatocyte proliferation 
and apoptosis were evaluated by BrdU incorporation and TUNEL 
assays, respectively. Enhanced BrdU incorporation was observed 
in 10-week-old AlbCrePtenflox/+ and AlbCrePtenflox/flox mice (Figure 
6A). The percentages of BrdU+ cells in the livers of AlbCrePten+/+, 
Figure 4
Expression of adipogenic and lipogenic genes in 
the absence of hepatic Pten. (A) RT-PCR analy-
ses of the indicated genes in +/+, flox/+, and flox/
flox livers. The relative intensity of each ampli-
fied PCR band as measured by NIH Image was 
as follows: PPARγ +/+, 1; flox/+, 2; flox/flox, 8; 
PPARα (1, 1, 1); C/EBPα (1, 1, 1); C/EBPβ (1, 
1, 0.7); C/EBPδ (1, 1, 1); SREBP1c (1, 1.5, 3); 
adiponectin (1, 1, 4); adipsin (1, 1, 4); aP2 (1, 1, 
4); FAS (1, 1, 3); ACC (1, 1, 2); SCD1 (1, 1, 2); 
AOX (1, 1, 2); L-PBE (1, 1, 2); PTL (1, 1, 2.5); 
β-actin (1, 1, 1). Data shown are representative 
of five independent experiments. (B) Expres-
sion of adipocyte-specific and hepatocyte-spe-
cific markers in the liver. Immunohistochemical 
double staining using antibodies specific for adi-
ponectin and albumin revealed the strong coex-
pression of these molecules in flox/flox liver cells 
(lower panel) compared with +/+ liver cells (upper 
panel). Magnification ×1000.
Figure 5
Liver tumors observed in AlbCrePtenflox/flox mice. (A) Macroscopic view of rep-
resentative liver adenomas (arrows) observed in 9/19 flox/flox mice of 40–44 
weeks of age. (B) H&E-stained section of a liver cell adenoma (T) in (A) flox/flox 
male mouse, showing its distinct demarcation from the surrounding nontumor-
ous liver tissue. The adenoma hepatocytes contain large quantities of lipid. (C) 
H&E-stained section of a flox/+ liver (male, 42 weeks). (D) Macroscopic view of 
a representative mutant liver (male) showing the HCCs observed in 8/12 flox/
flox mice at 74–78 weeks of age. (E) H&E-stained section of the flox/flox (male) 
liver in (D), showing an HCC with a trabecular-like arrangement that disrupts 
normal liver architecture. (F) Lung of the mouse in D, showing a metastasis (T). 
Magnifications are ×40 (B), ×400 (C), ×400 (E), and ×400 (F).
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AlbCrePtenflox/+, and AlbCrePtenflox/flox mice were 0.9, 1.5, and 7.0%, 
respectively. No significant differences in hepatocyte apoptosis 
were observed at either 10 or 40 weeks (Figure 6B).
We previously reported that regulation of PKB/Akt activation 
by Pten is critical for the normal apoptosis of mouse embryonic 
fibroblasts and for both proliferation and apoptosis of T cells, B 
cells, and keratinocytes (14, 18, 26, 27). MAPK, a major signaling 
molecule acting downstream of Ras, is also activated downstream 
of PIP3 (28). Our previous demonstration that both MAPK and 
PKB/Akt are activated in Pten-deficient cells (14, 27) prompted 
us to analyze the phosphorylation of PKB/Akt and MAPK in 
hepatocytes from 10-week-old AlbCrePtenflox/+ and AlbCrePtenflox/flox 
mice. Indeed, phosphorylated PKB/Akt, its downstream substrate 
phosphorylated Foxo1, and phosphorylated MAPK (extracellular 
signal-related kinases 1 and 2; ERK1/2) were significantly increased 
in AlbCrePtenflox/flox hepatocytes compared with WT cells (Figure 
6B). Thus, hepatocytes require Pten function to regulate PKB/Akt 
and MAPK signaling.
Increased production of reactive oxygen species (ROS) by 
hepatocytes has been associated with HCC development (29). 
We measured levels of H2O2 in liver homogenates from 10-week-
old AlbCrePtenflox/+ and AlbCrePtenflox/flox mice. The hepatic H2O2 
concentration in the mutant liver was increased sevenfold over 
that of the WT (Figure 6D). Taken together, our data suggest that 
dysregulation of cell survival signaling pathways and increased 
production of tumorigenic ROS can combine to drive hepatic 
tumorigenesis in the absence of Pten.
Discussion
Pten deficiency leads to steatohepatitis. A surprising finding of this 
study was that Pten deficiency causes lipid accumulation in 
hepatocytes. As a result, the mutant animals exhibit steatohepati-
tis similar to that observed in humans with NASH.
Several reports link adipocyte differentiation and the PI3K path-
way. Insulin receptor substrate-1–deficient (IRS-1–deficient) pre-
adipocyte cell lines stimulated with insulin and WT pre-adipocyte 
cell lines treated with a PI3K inhibitor both show blocked differen-
tiation, decreased lipid accumulation, and a striking reduction in 
PPARγ expression (30). Akt1/Akt2 doubly deficient mice also show 
impeded adipogenesis due to impaired induction of PPARγ (31). 
PKB/Akt directly phosphorylates and inactivates Foxo1, and con-
stitutively active Foxo1 inhibits the induction of PPARγ expression 
and adipocyte differentiation (32). Thus, adipogenesis triggered 
by the actions of the insulin and IGF-1 receptors and their down-
stream effectors IRS-1 and IRS-2 requires signaling through the 
PI3K-PKB/Akt-Foxo1-PPARγ pathway.
Another key player in adipogenesis is SREBP1, a transcription 
factor that regulates cholesterol and fatty acid homeostasis (25). 
Insulin-mediated activation of the PI3K-PKB/Akt pathway increas-
es SREBP1c expression in cultured rat hepatocytes (33). Ectopic 
expression of SREBP1c increases PPARγ expression and activity 
(34) and enhances FAS expression in cultured fibroblasts and in the 
livers of transgenic mice (35). SREBP1c promotes adipogenesis in 
cells stimulated with multiple hormonal inducers (35). Thus, lipid 
accumulation in Pten-deficient liver may be due to the coopera-
tion of the PI3K-PKB/Akt-Foxo1-PPARγ pathway with PI3K-medi-
ated SREBP1c induction. Indeed, mice that transgenically express 
PPARγ1 in the liver show massive steatosis (10). Moreover, mice 
with liver-specific deficiency of PPARγ show the opposite pheno-
type to our liver-specific Pten-deficient mice — namely, reductions 
in the lipogenic genes FAS, ACC, and SCD1, decreased hepatic 
steatosis (in A-ZIP transgenic background), and reduced insulin 
sensitivity (36, 37). Our data are thus the first to demonstrate that 
hepatic deficiency of Pten activates lipogenic mechanisms.
Loss of Pten expression in the liver enhances both the expres-
sion of the adipocyte-specific markers adiponectin, adipsin, 
Figure 6
Increased hepatocyte proliferation, phosphorylation 
of PKB/Akt, Foxo1, and MAPK (ERK1/2), and H2O2 
production in AlbCrePtenflox/flox mice. (A) Enhanced 
hepatocyte proliferation. Left panel: BrdU+ hepatocytes 
(arrows) were counted 4 days after administra-
tion of BrdU in drinking water. Right panel: data 
are expressed as the mean percentage of BrdU+ 
hepatocytes ± SEM for 1 × 104 cells per mouse for 
four mice per group. (B) No effect on apoptosis. Left 
panel: TUNEL+ hepatocytes (arrows) were counted. 
Right panel: data are expressed as the mean per-
centage of TUNEL+ hepatocytes ± SEM for 1 × 104 
cells per mouse for four mice per group. For A and 
B, results shown are one experiment representative 
of 3 trials. (C) Increased phosphorylation of signal 
transducers. The phosphorylated forms of PKB/Akt, 
Foxo1, and ERK1/2 in liver lysates of the indicated 
genotypes were determined by immunoblotting. Total 
PKB/Akt, Foxo1, and ERK1/2 levels were evaluated 
as controls. (D) Increased H2O2 production. H2O2 
concentrations in liver homogenates from 10-week-
old +/+, flox/+, and flox/flox mice were determined by 
the phenol red method. Results are expressed as the 
mean H2O2 produced ± SEM for four mice per group 
and are representative of three trials.
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and aP2, and the appearance of lipid vacuoles in hepatocytes. 
Immunohistochemistry confirmed that the albumin-express-
ing cells in mutant livers also expressed adiponectin (Figure 4B). 
We speculate that the tremendous accumulation of lipids in the 
mutant hepatocytes was due to an upregulation of PPARγ that 
resulted in the appearance of adipocyte markers and fat droplets.
Pten deficiency promotes hepatic tumorigenesis. Hepatic deficiency of 
Pten also leads to the development of liver tumors. Such malig-
nancies can arise due to dysregulation of enzymes that neutral-
ize free radicals. The inducible classical peroxisomal β-oxidation 
system consists of the H2O2-generating enzymes AOX, L-PBE, and 
PTL (38). Disproportionate increases in these H2O2-generating 
enzymes, coupled with reductions in the H2O2-degrading enzymes 
catalase and glutathione peroxidase, may lead to sustained oxi-
dative stress in the liver (39). As a result, hepatocytes may pro-
gressively accumulate lipofuscin, a by-product of ROS-induced 
lipid peroxidation. The formation of 8-hydroxydeoxyguanosine 
adducts in liver DNA also occurs under conditions of excess H2O2 
(40). This metabolically induced oxidative DNA damage may pre-
dispose hepatocytes to malignant transformation. Interestingly, 
hepatocytes with sustained PPARγ activation show increased 
expression of PPARα-induced H2O2-generating enzymes in vitro 
(12) and in vivo (10). Our data show that Pten deficiency increases 
the activation of PPARγ- and PPARα-regulated genes, although 
the expression of PPARα itself is not enhanced. While an increase 
in endogenous PPARα ligands could theoretically activate PPARα-
regulated genes, peroxisome proliferation (which is usually asso-
ciated with upregulated endogenous PPARα ligands; see ref. 41) 
was not observed in our Pten-deficient mice. Rather, we theorize 
that DNA damage due to PPARγ-mediated upregulation of H2O2-
generating enzymes, coupled with inflammatory cell infiltration 
plus increased hepatocellular proliferation due to abnormal acti-
vation of PKB/Akt and MAPK, may all combine to trigger the 
hepatic tumorigenesis observed in AlbCrePtenflox/flox mice. Several 
lines of evidence support our hypothesis. Administration of anti-
oxidants such as ethoxyquin along with peroxisome proliferators 
retards liver tumorigenesis (42), and peroxisome proliferators 
capable of inducing HCC development fail to do so in PPARα-
null mutant mice (43). Moreover, AOX-deficient mice develop 
HCC at 10–15 months of age as a result of sustained hyperac-
tivation of PPARα in the liver by its natural ligands (44). These 
observations bolster our contention that events downstream of 
PPARα may be critical for HCC onset.
The role of PPARγ in tumorigenesis is controversial. PPARγ acti-
vators can promote the development of colon tumors (45, 46), but 
loss-of-function PPARγ mutations occur in some human colon 
cancers (47). In mice, PPARγ agonists induce antineoplastic dif-
ferentiation (48) or growth arrest (49), and suppress chemically 
induced tumorigenesis (50, 51).
It is unclear whether the altered fatty acid composition 
observed in the AlbCrePtenflox/flox liver contributes to tumorigen-
esis. However, increased oleic acid (C18:1) and decreased stearic 
acid (C18:0) could increase membrane fluidity, leading to the 
increased metabolism and proliferation (52, 53) characteristic of 
malignant cells. Analyses of fatty acids present in lipid extracts 
of transformed cells show a consistent increase in oleic acid con-
tent relative to stearic acid (54, 55). Indeed, the ratio of oleic 
to stearic acid is increased in the livers of mice prone to HCC 
development, such as hepatitis virus C-core transgenic mice 
(19). Finally, while stearic acid can inhibit cancer cell growth, 
oleic acid abrogates this effect (53). The predominance of C18:1 
fatty acids in the AlbCrePtenflox/flox liver may induce hepatocytes 
to divide at an accelerated rate, promoting the acquisition of 
tumorigenic mutations.
SCD1 expression was also increased in the absence of Pten. SCD1 
is involved in the synthesis of oleic and palmitoleic acids (C16:1). 
SCD1 expression is positively regulated by SREBP1c, C/EBPα, and 
PPARα (56, 57) but negatively regulated by PPARγ ligands (58). 
However, PPARγ overexpression in mouse liver enhances SCD1 
expression (10), while PPARγ deficiency reduces it (36). Several 
treatments or conditions that are associated with hepatocarcino-
genesis (57, 59) also increase SCD1 expression, and SCD1 levels 
are higher in rat mammary carcinomas (60) and in mice that are 
genetically susceptible to hepatocarcinogenesis (61). Sterculic acid, 
an inhibitor of SCD1 activity, blocks rat mammary carcinogenesis 
(62). In our study, the increased SREBP1c expression observed in 
AlbCrePtenflox/flox mice may have induced SCD1 upregulation and 
an accumulation of monounsaturated fatty acids that may have 
promoted hepatocarcinogenesis.
Insulin sensitivity in AlbCrePtenflox/flox mice. Production of PIP3 
by PI3K is necessary for various metabolic responses to insulin, 
including PKB/Akt activation, glucose transport, and glyco-
gen and lipid synthesis. Because Pten dephosphorylates PIP3, 
Pten may act as a negative regulator of insulin stimulation. 
Overexpression of PTEN in 3T3-L1 cells inhibits glucose uptake 
and GLUT4 translocation in vitro (63), and administration of a 
Pten antisense oligonucleotide reverses hyperglycemia in db/db or 
ob/ob diabetic mice (64). In our study, Pten deficiency in the liver 
led to insulin hypersensitivity and enhanced glucose clearance. 
We speculate that Pten deficiency leads to an accumulation of 
PIP3 that drives constitutive insulin signaling.
Fatty liver is a feature of many mouse models of altered glu-
cose metabolism, including ob/ob (65) and aP2-SREBP1c trans-
genic mice (66). However, in contrast to AlbCrePtenflox/flox mice, 
these animals show hyperinsulinemia. Increased serum insulin 
may reduce IRS2 expression, resulting in only weak activation 
of the PI3K pathway and thus insulin resistance (67). Insulin 
resistance is a hallmark of human type II diabetes. Our findings 
thus suggest that molecular strategies that increase PI3K activi-
ty, elevate PIP3 concentration, and/or activate PI3K downstream 
effectors, may constitute novel therapeutic approaches for the 
treatment of type II diabetes.
Implications of the liver-specific Pten mutation for related human dis-
eases. NASH is a chronic liver disease in humans (68) characterized 
by steatohepatitis that can progress to irreversible liver cirrhosis 
and hepatocellular failure. The majority of NASH cases are associ-
ated with obesity, diabetes mellitus, and hyperlipidemia, but the 
underlying mechanism is unknown in the remainder. Whether 
HCC is a part of the natural history of NASH has been controver-
sial, although some HCC patients do exhibit NASH (68). While 
hepatic steatosis and insulin hypersensitivity in liver-specific 
Pten-deficient mice have recently been reported (69), our extended 
monitoring of our AlbCrePtenflox/flox mice revealed the occurrence 
of liver tumors and NASH-like pathological features (24) such as 
steatosis, Mallory bodies, pericellular fibrosis, and the presence of 
inflammatory cells. PTEN deficiency leading to abnormal PI3K 
activation may thus underlie some NASH cases. Indeed, hyperlep-
tinemia or estrogen administration can induce NASH in patients, 
and leptin and estrogen both activate PI3K (70, 71). The fact that 
our mutant mice go on to develop liver tumors suggests that HCC 
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is indeed a part of the natural history of NASH. Our results sug-
gest that the controlled blocking of molecules acting downstream 
of PI3K might provide significant therapeutic benefit to patients 
predisposed to NASH, liver cirrhosis, or HCC.
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